Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merrimack Pharmaceuticals, Inc.

http://www.merrimackpharma.com/

Latest From Merrimack Pharmaceuticals, Inc.

EQRx Reveals Two New Assets For Low-Cost Drug Pipeline

The start-up launched in January with $200m to develop lower-priced drugs against known targets. Now it has licensed a CDK4/6 inhibitor from G1 Therapeutics and an EGFR inhibitor from Hansoh.

Deals Business Strategies

Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement

The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.

Orthopedics Surgical Procedures

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.

Financing StartUps and SMEs

Finance Watch: Summer Slowdown Nears Its End With Strategic Shifts And IPO Hopes

Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
  • Other Names / Subsidiaries
    • Hermes Biosciences, Inc.
UsernamePublicRestriction

Register